Alternatively, treating the lung of SCLC patients with EVs produced by NSCLC cell lines to achieve lung tissue sensitivity to EGFR-TKIs may be one treatment strategy worthy of exploration. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.